Semaglutide;weight loss;CAS:910463-68-2;High Quality and High Purity Peptide;Wholesale Price

Connect with:Domi

WhatsApp:+86 18331965818

Email: domi@xtjytech.com  

Company Detail & Pictures:

Xingtai Junyi Technology Co.，Ltd. Was established in 2019. It mainly deals in peptide products, synthetic peptide amino acids, beauty and slimming products, and beauty freckle removal cosmetic raw materials. It has strong R&D capabilities, superb synthesis technology, and advanced quality control methods. It effectively promotes joint ventures with major companies and manufacturers, and serves the society and users with the concept of industrial development. It always adheres to market demand-oriented, continuously synthesizing new high-tech freckle and wrinkle removal beauty peptide products, which are mainly exported to the United States, Europe, South Africa, Nigeria and other countries and regions. It has rich export experience and ensures transportation safety.

Somalutide  is a new generation GLP-1 (glucagon-like peptide-1) analogue developed by NovoNordisk of Denmark. Somalutide is a long-acting formulation based on the basic structure of liraglutide and has a better therapeutic effect on type 2 diabetes.

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a promising therapeutic for T2DM management . Its pharmacological profile is characterized by high affinity and specificity for the GLP-1 receptor, coupled with a prolonged half-life of about one week due to albumin binding .

Semaglutide, like GLP-1, also has an effect on receptors in the peripheral and central nervous systems. In the context of metabolic disease, uncontrolled T2DM can lead to peripheral neuropathy. GLP-1 receptors are found diffusely in both the peripheral and central nervous systems. It has been suggested that semaglutide may exert benefits in improving symptoms like peripheral neuropathy, beyond glycemic control. The central effects of semaglutide on energy homeostasis are mediated through its action on GLP-1 receptors in the hypothalamus and brainstem, leading to reduced appetite and food intake . The mechanism of reduced appetite is complex but appears to involve neural circuits of the vagus nerve . Additionally, semaglutide has been shown to delay gastric emptying, further contributing to its weight loss effects .

Mechanism of Action
In developing semaglutide, prioritizing the fatty acid moiety and linking chemistry was crucial for achieving high albumin affinity and GLP-1 receptor (GLP-1R) potency, enabling prolonged exposure of the GLP-1 analogue. As a result, semaglutide incorporates two amino acid substitutions (Aib8, Arg34) and is modified at lysine 26 . This modification makes the drug's half-life of 165 hours .
At the molecular level, semaglutide's mechanism of action involves the GLP-1 receptor (GLP-1R), a G-protein coupled receptor . Upon binding to GLP-1R, semaglutide leads to increased intracellular cyclic adenosine monophosphate (cAMP) levels, activating protein kinase A (PKA). PKA is involved in the synthesis and secretion of insulin but inhibits the release of glucagon. Increased levels of cAMP can also activate the Rap1 via EPAC (Exchange Protein directly Activated by cAMP), which is involved in regulation of insulin secretion . Semaglutide, mimicking GLP-1 signaling, can also activate the PI3K/Akt pathway involved in maintenance and viability of pancreatic β-cells . In pancreatic β-cells, this signaling cascade also enhances glucose-dependent insulin secretion and sensitivity of peripheral tissues to insulin. Simultaneously, semaglutide suppresses glucagon secretion by pancreatic α-cells, contributing to improved glycemic control .
Semaglutide, like GLP-1, also has an effect on receptors in the peripheral and central nervous systems. In the context of metabolic disease, uncontrolled T2DM can lead to peripheral neuropathy. GLP-1 receptors are found diffusely in both the peripheral and central nervous systems. It has been suggested that semaglutide may exert benefits in improving symptoms like peripheral neuropathy, beyond glycemic control . The central effects of semaglutide on energy homeostasis are mediated through its action on GLP-1 receptors in the hypothalamus and brainstem, leading to reduced appetite and food intake . The mechanism of reduced appetite is complex but appears to involve neural circuits of the vagus nerve . Additionally, semaglutide has been shown to delay gastric emptying, further contributing to its weight loss effects.

Factory Pictures

Connect With:Domi

WhatsApp:+86 18331965818

Email: domi@xtjytech.com

A. Cardioprotective Effect

The SUSTAIN-6 trial provided compelling evidence for the cardiovascular benefits of semaglutide, demonstrating a 26% reduction in the risk of major adverse cardiovascular events in T2DM patients with elevated cardiovascular risk.

B. Glycemic Control

Semaglutide therapy has also garnered attention for its potential therapeutic effects for Alzheimer’s Disease. Alzheimer’s Disease is a neurodegenerative disease characterized by dementia and cognitive impairment in language, comprehension, memory and more . Specifically, semaglutide therapy has been associated with associated with decreased amyloid-beta plaque deposition and neuroinflammation. It’s effects on the central and peripheral nervous system are thought to mediate these effects, party through ability to cross the blood-brain barrier.

C. Weight Loss

D. Chronic Kidney Disease (CKD)